


Name	Arata Azuma, MD, PhD	
Country	Japan	
Organization	Mihara General Hospital / Nippon Medical School, Japan	
Current Position	Professor	

Education	1983: Graduated from Nippon Medical School
	1983-88: Resident (Pulmonary medicine, Clinical oncology)
	1989-91: Research work (Department of Immunology, Juntendo University)
	1991-: MD, PhD, Nippon Medical School, Tokyo, Japan

Academic Career

1994 – present	Secretary General of the ‘Research Group on Novel Effects of Macrolides’
1996	Assistant Professor of Pulmonary Medicine, Nippon Medical School
1999 – present	Member of a research group of the Ministry of Health, Welfare and Labor(MHWL) of JAPAN (Research on Pathogenesis of Diffuse Parenchymal Lung Diseases)
2002 – present	Member of a research group of the Ministry of Health, Welfare and Labor of JAPAN (Strategy for Clinical Research on Treatment of Idiopathic Interstitial Pneumonias)
April 2002 – present	Member of the International Committee Meeting of the Japanese Respiratory Society
2004 -	Associate professor of Pulmonary medicine, Nippon medical School
2008 -	Visiting Professor of Tongji University, School of Medicien (Shanghai)
2008.10 -	Professor of Graduate School of Medicine, Department of Pulmonary, Infection and Oncology in Nippon Medical School
2010 to 2012	National Delegate of ERS-Japan
2010. 4-	Director of Asian Pacific Thoracic Academy (APTA)
2011. 1-	WASOG vice president
2011. 3-	Global Steering Committee member for INPULSIS trial
2011. 6-	PMDA committee member for survey of adverse drug reaction
2013. 4 -	Visiting Professor of National University of Mie
2013. 4-	Associate Editor of Respirology Case Reports Journal
2013. 12 -	Part-time Assistant Professor of National University of Kyoto
2016. 4-	Research Associate of National University of Mie
2016. 5-	Visiting Professor of Nevada University

2017.10-2020.10 President of WASOG

2018.10- Education Committee Chair of APSR

2019.10 Conference Chair of WASOG/JSSOG in Japan

2303.4 Chair of Respiratory Medicine and Clinical Research Center,

2023.9 President of JSSOG

Awards, Honors and Foundation officer

July 2000 Research on Pulmonary Fibrosis Award (Okamoto Award)

August 2002 Award for Research on Diffuse Lung Diseases (from Nippon Medical School)

2016. 6- Auditor of **Japanese Respiratory Foundation**

2019.11 Harasawa Memorial Award of APSR

Recent Research Activities

- Interests: 1) Diffuse lung diseases (pathogenesis of interstitial pneumonia, relationships to environmental factors and occupation, genetic predisposition to diffuse panbronchiolitis, pathogenesis of sarcoidosis, pulmonary proteinosis, hypersensitivity pneumonitis, etc.). 2) novel effects of macrolide derivatives (non-antibiotic anti-inflammatory effects)
- Institutional organizer for clinical trials of new compounds for IPF:
 - neutrophil elastase inhibitor (ONO-5046),
 - lecithinized-SOD (PC-01C),
 - anti-fibrotic agent (Pirfenidone); Phase-2, Phase-3 organization. (Japan Trials)
- International Steering Committee Member of Nintedanib (BIBF1120) for IPF, Phase-3 trial (from 2010.12 – 2014.10)
- International Advisory Board Member of Nintedanib (BIBF1120) for IPF (from 2014.10 -)
- International drug-safety monitoring board (DSMB) member of Tofacitinib (CP690,550, old name; Tasocitinib) for Rheumatoid Arthritis, 2010 – 2015.
- PMX-DHP(direct hemoperfusion) for Acute Exacerbation of IPF. Organizer in Ministry of Health, Labor and Welfare (MHLW) of Japan. 2008 – 20xx.
- Novel Action of Macrolide Research Group, Organizer. 1994 – 20xx.
- Post Marketing Surveillance of pirfenidone in Japan, Advisory Board Member. 2009 – 20xx.
- A Member of Review Board of Drug related adverse events and New Drug Evaluation, in PMDA (Pharmaceuticals and Medical Devices Agency; <http://www.pmda.go.jp/>). 2011-20xx.
- Chief Investigator of PC-SOD (LTT Bio) for IPF, Cooperative Clinical Trial (Japan and Korea) (from 2010.10)
- PASSPORT (post-authorization safety registry of pirfenidone in EU) Advisory Board Member (2013.12-)
- GSK new drug development Advisory Board Member (2015, March-)
- Steering Committee Member of SSc-ILD Trial with Nintedanib (SENSCIS: 1199.247) (2016.10-)
- Advisory Board Member of PF-ILD (progressive fibrosis ILD) Trial with Nintedanib (2016.10-)
- REG (Respiratory Effectiveness Group) -ILD steering committee member (Chair: Luca Richeldi)
- Advisory Board Member of BBT-877 (anti-autotaxin) BridgeBio (2019. May 20-)

- Principal Investigator of **BNC-1021/TRK-250; BONAC/COVANCE** for IPF (2019. October -)
- Principal Investigator of **ATYR1923 (FSR/Kyorin Pharm)** for Sarcoidosis (2019. October -)
- Principal Investigator of **TAS-115 (Taiho Pharm)** for IPF and PF-ILD (2019 May -)
- Advisory Board Member of Acid sphingomyelinase deficiency(AISF) (Sanofi) (2020 August-)
- Steering Committee Member of **BI 1015550(PDE4Bi)** for IPF (2020, 24 January-)

- **Selected Publications in recent years** (focused on diffuse lung diseases):

- **Am J Respir Cell Mol Biol** 32(2): 93-98, 2005; Interferon- β Inhibits Bleomycin-Induced Lung Fibrosis by Decreasing Transforming Growth factor- β and Thrombospondin. **Azuma A**, Li YJ, Abe S, Usuki J, Matsuda K, Henmi S, Miyauchi Y, Ueda K, Izawa A, Sone S, Hashimoto S, Kudoh S.
- **Am J Respir Crit Care Med** 171: 949-957, 2005; Kamio K, Matsushita I, Hijikata M, Kobashi Y, Tanaka G, Nakata K, Ishida T, Tokunaga K, Taguchi Y, Homma S, Nakata K, **Azuma A**, Kudoh S, Keicho N. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis.
- **Am J Respir Crit Care Med** 171: 1040-1047, 2005; **Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.** **Azuma A**¹, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S.
- **Respir Res**, 7(1): 16, 2006; Li YJ, **Azuma A**, Usuki J, Abe S, Matsuda K, Sunazuka T, Shimizu T, Hirata Y, Inagaki H, Kawada T, Takahashi S, Kudoh S, Omura S. EM703 Improves Bleomycin-Induced Pulmonary Fibrosis in Mice by the Inhibition of TGF- β Signaling in Lung Fibroblasts.
- **Eur Respir J** 35: 821-829, 2010; H Taniguchi, M Ebina, Y Kondoh, T Ogura, **Azuma A**, M Suga, Y Taguchi, H Takahashi, K Nakata, A Sato, M Takeuchi, G Raghu, S Kudoh, T Nukiwa. Pirfenidone in IPF.
- **Am J Physiol-Lung Cellular and Molecular Physiology** 298(3): L348-360, 2010; Tanaka K, Ishihara T, **Azuma A**, Kudoh S, Ebina M, Nukiwa T, Sugiyama Y, Tasaka Y, Namba T, , Mizushima T. PC-SOD inhalation
- **Blood Purification** 29(4): 321-6, 2010; Abe S, Seo Y, Hayashi H, Matsuda K, Usuki J, **Azuma A**, Kudoh S, Gemma A. Neutrophil Adsorption by Polymyxin B-immobilized Fiber Column for Acute Exacerbation in Patients With Interstitial Pneumonia: A Pilot Study.
- **J Intensive Care Med.** 36(5): 906-907, 2010.; Hypercytokinemia With 2009 Pandemic H1N1 (pH1N1) Influenza Successfully Treated With Polymyxin B-immobilized Fiber Column Hemoperfusion. Takeda S, Munakata R, Abe S, Mii S, Suzuki M, Kashiwada T, **Azuma A**, Yamamoto T, Gemma A, Tanaka K.
- **Biochem Pharmacol.** 80(6): 920-31, 2010.; Heat Shock Protein 70 Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice. Tanaka K, Tanaka Y, Namba T, **Azuma A**, Mizushima T.
- **Human Genetics** 129: 117-128, 2011. Hijikata M, Matsushita I, Tanaka G, Tsuchiya T, Ito H, Tokunaga K, Ohashi J, Homma S, Kobashi Y, Taguchi Y, **Azuma A**, Kudoh S, Keicho N. Molecular Cloning of Two Novel Mucin-Like Genes in the Disease-Susceptibility Locus for Diffuse Panbronchiolitis
- **Respiratory Research** 12: 93, 2011.; 5%change of %VC
- **Public Library of Science (PLoS) One** 6(11): e27296, 2011.; Namba T, Tanaka K, Hoshino T, **Azuma A**, Mizushima T. HSP70 inhibition by gefitinib
- **Current Opinion in Pulmonary Medicine** 17(5): 303-307, 2011.; Sarcoidosis vs IPF (Review)
- **Respiratory Research**, 12:143, 2011.; pirfenidone phase III sub analysis >70% of VC

- *Respirology*, 17(3):467-77, 2012. NAC for IPF
- Am J Physiol - Lung Cellular Mol Physiol*, 2012.; IgM type for GM-CSF in PAP
- Am J Physiol - Lung Cellular Mol Physiol*, **302**: L1250-L1261, 2012 ; PC-SOD COPD mice, pulmonary function
- *Intern Med*. 51(12): 1487-91, 2012.; Retrospective analysis in PMX-DHP for AE of IPF.
- Sarcoidosis Vasculitis and Diffuse Lung Diseases* **29**: 19-25, 2012.; DPB prevalence in Japan
- *Biochem Biophys Res Commun*. **424(1)**:112-7, 2012.; Fut8 in COPD
- Eur Respir J* **40**: 485-494, 2012. ML for COPD exacerbation (Review)
- *Therapeutic Advance in Respiratory Diseases* **6(2)**: 107-114, 2012.; pirfenidone (Review)

- Community Acquir Infect* 2014;1:6-10. Macrolide antibiotics: 25y of use and future treat. (Review)
- *Respir Res*, 2014. Feb 8;15:16. doi: pirfenidone inhibits fibrocyte.
- *New Engl J Med* 2014, May 18. INPULSIS trial (1199.32, 1199.34).
- Sarcoidosis Vasc Diffuse Lung Dis*. 2014 Apr 18;31(1):19-27. Organ Assessment of Sarcoidosis.
- *J Pharmacol Exp Ther*. 2014 Apr 25. Mepenzolate ameliorates fibrosis.
- *Pulmonary Medicine* 2014, 14:86. PC-SOD inhibits SP-A in div trial.
- Pulmonary Medicine* 2014, 14(1):104. CPFE: correlation with pathology.
- *Sarcoidosis Vasculitis and Diffuse Lung Dis*. 2014; 31: 235-238. Pirfenidone inhibits SSc-ILD. Miura Y
- *Eur Respir J* 2014. Pirfenidone and Nintedanib. Ogura T

- *Am J Respir Crit Care Med*. 2015 Jul 15;192(2):e3-e19. EB guideline.
- *World J Respirol* 2015 March 28; 5(1): 4-16. Sarcoidosis, Inomata M.
- *Expert Opinion on Orphan Drug*. 3(5): 587-597, 2015. Pirfenidone, Miura.
- Pulm Pharmacol Ther*. 2015 Jun;32:29-36. SP-D Nintedanib, Kamio K.
- Clin Respir J*. 2015 Feb 17. Ig for IPF, Enomoto N.
- Sarcoidosis Vasculitis and Diffuse Lung Disease* **31**: 325-335, 2015. Mochimaru, H.
- Respir Investig*. 53(2):51-9, 2015. National Registry of IPF. Bando M.
- Sarcoidosis Vasc Diffuse Lung Dis*. **2015**. Sarcoidosis in Kidney. Kamata,
- Respir Investig*. 2015 Nov;53(6):271-8. Kondoh Y, risk for AE-IPF.
- Respir Investig*. 2015 Nov;53(6):279-87. Taguchi Y, extended analysis of phase III of PFD for IPF.
- Respir Investig*. 2015 Nov;53(6):288-95. Miyazaki Y, CyA for severe IPF.
- Core Evid*. 2015 Aug 27;10:89-98. Inomata M, Nintedanib Review

- *Am J Respir Crit Care Med*, **2016**. Costabel U, INPULSIS sub analysis.:

Hum Pathol. 2016 May;51:57-63. Kokuho N, Pulm Lymphoma in Sarcoidosis.

Int J Chron Obstruct Pulmon Dis. 2016 Mar 29;11:649-55. Kubota Y, Left ventricular dysfunction in COPD

Intern Med. 2016. 55(5):443-8. Bando Y, Long term use of PFD.

Respirology. 2016 Jul 11. doi: 10.1111/resp.12852. Taniguchi Y, Asian Sub analysis of INPULSIS.

J Allergy Clin Immunol. 2016 Jul;138(1):281-283. Yatagai Y, HCG22 gene for Asthma.

• **Respir Res.** 2016 Jul 22;17(1):90. Iwata T, Yoshino I, **Azuma A**, et al. PFD for surgery induced AE-IPF.

Respirology. 2016 Sep 11. doi: **Azuma A**, Japanese Sub Analysis of INPULSIS.

Respir Investig. 2017 Jan; 55(1) 1. **Azuma A**, **Editorial.** Safety management of Nintedanib for IPF.

Pulm Pharmacol Ther. 2017 Mar 14. pii: S1094-5539(16)30204-8, Kamio K, **Azuma A**, XPLN is modulated by HDAC inhibitors, SPARC.

Int J Mol Sci. 2017 Mar 17;18(3). pii: E649. Li YJ, Azuma A, Nrf2_Diesel Exhaust Inhalation

Respir Physiol Neurobiol. 2017. 242:108-116, Aug Tanaka T, NOX type II cell

Intern Med. 2018 Mar 1;57(5):655-661. Atsumi K, prognostic factors for AE-IPF

Respir Investig. Jan;56(1):72-79, 2018. Miura Y, **Azuma A**. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.

Respir Res. Apr 24;19(1):71, 2018. Kamio K, **Azuma A**, Treg resolves BLM induced fibrosis.

Heart Rhythm. 2018 Jun;15(6):798-802. Yodogawa K, Seino Y, **Azuma A**, et al. Prognostic significance of ventricular late potentials in patients with pulmonary sarcoidosis.

SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2018; 35; 252-260. Kamata Y. Kidney Sarcoidosis

Respir Investig. 2018 Jul;56(4):268-291. Homma S, Bando M, **Azuma A**, et al.; Japanese guideline for the treatment of idiopathic pulmonary fibrosis.

• **Am J Respir Crit Care Med.** 2018 Sep 1;198(5):e44-e68. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, **Azuma A**, et al; Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Respir Investig. 2018 Jul;56(4):268-291. Homma S. Japanese GL for IPF.

ERJ Open Res. 2018 Oct 19;4(4). Cottin V, Koschel D, Günther A, Albera C, **Azuma A**, et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.

Respir Med. 2019 Jan;146:42-48. Brown KK, Flaherty KR, **Azuma A**, et al. Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis .

Eur Respir J. 2019 Jan 17. Cottin V, **Azuma A**, et al. Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. (Epub)

Int J Mol Sci. 2019 May 7;20(9). Yoshida GJ, CAF review.

• **New Engl J Med** 2019 May 20. Distler O, SENSICIS trial (Nintedanib for SSc-ILD).

Int J Clin Oncol. 2019 Dec;24(12):1543-1548. Weekly Paclitaxel in Combination With Carboplatin for Advanced NSCLC in IPF.

Respir Med. 2019 Sep;156:20-25. INPULSIS and INPULSIS-ON Trials of Nintedanib.

- **Circulation J.** 2019. 83(11):2329-2388. Terasaki F, Azuma A, et al. CS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis.
- **Mol Genet Genomic Med.** 2020. e1033, Keicho N, Azuma A, et al. Primary Ciliary Dyskinesia
- **Mod Rheumatol.** 2020 30(2):225-231. Kuwana M, Azuma A. Nintedanib: New Indication for SSc-ILD.
- **Am J Respir Crit Care Med.** 2020 201(9):1110-1119. Kondoh Y, Azuma A, Inoue Y, et al. Thrombomodulin Alfa for Acute Exacerbation of IPF.
- **Respirology.** 2020, 25(5):472-474. Morimoto Y, Khatun H, Yee KSW, Susanto AD, Myong JP, Tanchuco JJ, Sheu CC, Chau NQ, Azuma A. Air Pollution.
- **Mod Rheumatol.** 2020 Apr 23:1-10. Kuwana M, Azuma A. Nintedanib for SSc-ILD in Japan.
- **Int J Cardiol.** 2020 Aug 15;313:55-59. Yodogawa K, Azuma A, Shimizu W. FDG-PET in Sarcoidosis.
- **Chest.** 2020 Apr 29:S0012-3692(20)30778-9. Sweiss NJ, Korsten P, Syed HJ, Syed A, Baughman RP, Yee AMF, Culver DA, Sosenko T, Azuma A, Sarcoidosis in COVID19 Pandemic.
- **ERJ Open Res.** 2020 May 26;6(2):00184-2019. Minegishi Y, Gemma A, Homma S, Kishi K, Azuma A, AE-IIPs related chemotherapy in lung cancer.
- **Tuberc Respir Dis (Seoul).** 2020 Apr 29. Azuma A, Richeldi L. New Era of Management Concept on Pulmonary Fibrosis With Revisiting Framework of Interstitial Lung Diseases.
- **Ann Rheum Dis.** 2020 Nov;79(11):1478-1484. Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Distler O; SENSICIS trial investigators. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial.
- **Biomedicines.** 2020 Oct 21;8(10):443. Li YJ, Shimizu T, Azuma A, Yamamoto M, Kawada T. Nrf2 Lowers the Risk of Lung Injury via Modulating the Airway Innate Immune Response Induced by Diesel Exhaust in Mice.
- **Case Rep Nephrol Dial.** 2020 Oct 12;10(3):109-116. Kamata Y, Sato H, Azuma A. A Case Demonstrating the Pathological Relationship between Granulomatous Vasculitis and Glomerular Lesion in Renal Sarcoidosis.
- **Respir Res.** 2020 Nov 30;21(1):316. Ikeda K, Chiba H, Nishikiori H, Azuma A, Nukiwa T, Kudoh S, Takahashi H; Pirfenidone Clinical Study Group in Japan. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
- **Respir Investig.** 2021 Mar;59(2):252-259. Azuma A, Chung L, Kuwana M; SENSICIS trial investigators. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSICIS trial.
- **Lancet Respir Med.** 2021 Jan;9(1):96-106. Highland KB, Distler O, Kuwana M, Azuma A, Maher TM; SENSICIS trial investigators. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial.
- **Exp Cell Res.** 2021 Inomata M, Kamio K, Azuma A, Gemma A. Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis.
- **J Arrhythmia** 37(2) 438-444. Maru Y, Yodogawa K, Azuma A, W Shimizu. Detection of cardiac involvement in pulmonary sarcoidosis using high-resolution Holter electrocardiogram.

- **Chest 2021**. Suzuki A, Sakaguchi H, , Azuma A, , Kondoh Y. The Effect of Pirfenidone on the Prescription of Antibiotics and Antitussive Drugs in Patients With Idiopathic Pulmonary Fibrosis: A Post Hoc Exploratory Analysis of Phase III Clinical Trial.
- **Contemporary Clinical Trials Communications 2021** 23: 100832-100832. Nishioka Y, Homma S, Okubo T, Azuma A. Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis.
- **Blood purification** 1-7 2021. Oishi K, Azuma A, Abe S, Murata Y, Sakamoto K, Yusuke Mimura Y, Asami-Noyama M, Kakugawa T, Hirano T, Matsunaga K. Improved Prognostic Prediction by Combination of Early Initiation of Polymyxin B Hemoperfusion with Modified Gender-Age-Physiology Index in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
- **N Engl J Med 2022**;386;23:2178-2187. Luca Richeldi, Arata Azuma, Vincent Cottin, , Toby Maher. Trial of a Preferential Phosphodiesterase 4B Inhibitor for IPF.
- **Ann Rheum Dis 2022**; 0:1–8. doi:10.1136. Allanore Yannick, Madelon C Vonk , Oliver Distler , Arata Azuma, Maureen D Mayes, Martina Gahlemann, Alexandra James, Veronika Kohlbrenner, Margarida Alves, Dinesh Khanna, Kristin B Highland, on behalf of the SENSCIS-ON trial investigators. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.



Grants

- April 1995 – March 1996 Grant for Scientific Research from the Ministry of Education – General Research (C)
Subject: Basic research on antibody therapy against lung cancer cells using a humanized chimera antibody
- April 1998 – March 2000 Co-investigator, Grant for MHW Priority Scientific Study Group; Principal Investigator, Shoji Kudoh
Subject: Development of cellular/molecular pathology-specific treatment of idiopathic interstitial pneumonia
- April 1998 – present Co-investigator, Study on Health Effects of Pollution, funded by the Ministry of the Environment
Subject: Experimental study of effects of airborne particulates on the respiratory system
- July 25, 2000 Awarded Okamoto Toshi Research Grant for Pulmonary Fibrosis in 2000 by Toyo Trust Bank
Subject: Study of inhibition of bleomycin-induced pulmonary fibrosis by macrolides
- 2000-2001 Principal Investigator, Grant for Scientific Research from the Ministry of Education – Basic Research (C-2)
Subject: Basic therapeutic research on inhibition of endothelial cell adhesion and tissue invasion in interstitial pneumonia.
- 2002-2004 Principal Investigator, Grant for Scientific Research from the Ministry of Education – Basic Research (C-2), (14570569)
Subject: Study of the mechanism of intracellular inhibitory effects of interferons γ and β in interstitial pneumonia and pulmonary fibrosis.
- 2002-2003 Co-investigator, Grant for Scientific Research from the Ministry of Education – Exploratory Research
Subject: Study of effects of exposure to diesel exhaust on tuberculosis infection
- August 7, 2002 The 70th Scholarship from Nippon Medical School
Subject: Clarification of etiology and pathology of diffuse lung disease and development of methods of treatment of it
- 2002 – 2004 Co-investigator, Scientific research grant from the MHLW



MHLW Priority Disease Study Group on Diffuse Lung Disease
(Director: Toshihiro Nukiwa)

- April 1998 – present Co-investigator, Study on health effects of pollutants, funded by the Ministry of Environment
Subject: Experimental research on effects of airborne particles on the respiratory system
- 2003-2005 Co-investigator, Grant for scientific research from the MHLW
Research project to overcome intractable diseases (Director; Shoji Kudoh)
Subject: Clinical research on breakthrough treatment for idiopathic interstitial pneumonia
(15180401)
- 2005-2007 Principal Investigator, Grant for Scientific Research from the Ministry of Education – Basic
Research (C-2), (17590806)

Subject: Basic research on drug-induced acute lung injury and its
mechanism of action in Japanese.
- 2011-2013 Principal Investigator, Grant for Scientific Research from the Ministry of Education – Basic
Research (C-2), (23591163)

Subject: Basic research on bonemarrow derived progenitor cell in
fibrosis and research on efficacy evaluation of novel agents.
- December 2004 **Award for Best Presentation.** 9th Asian Pacific Society of Respirology (APSR)
Subject: EM703 - New Derivative of Erythromycin: Improvement of Pulmonary Fibrosis in
Bleomycin-Challenged Mice by Regulation of Smad 3 Messenger RNA Expression.
- November 24, 2005 **Awarded** Suzuki Kenzo Research Grant in 2005 by Toyo Trust Bank
- August 22, 2006 **Awarded** Imai Kenzo Research Grant for Sarcoidosis in 2006 by Toyo Trust Bank. Subject:
Development of high sensitive assay method of ERISPOT for diagnosis of Sarcoidosis.
- November 24, 2006 Asian Pacific Society of Respirology (APSR), Education Committee Member.
- September 1, 2015 Assembly **Head Elect of ILD** in APSR
- November 1, 2017 Assembly **Head of ILD** in APSR

November, 2018. **Education Committee Chair** of APSR

Invited Lecture:

1. Lecture for certified physicians and specialists: "A comparison of bronchoscopic biopsy and thoracoscopic biopsy in patients with diffuse lung disease". Kanto District Meeting of the Japan Society for Respiratory Endoscopy, 1999.2.
2. **Invited Lecture:** "Idiopathic interstitial pneumonia". 20th Annual Meeting of Japanese Inflammation Society, 2000.7.
3. **Luncheon Seminar:** "Aspects for treatment of idiopathic interstitial pneumonia". 26th Annual Meeting of Japanese Bronchology Society (Tokyo, Nagata), 2003.5.
4. **Invited Lecture** at Nebraska Medical Center: "**New Concept of Strategy for Treatment in Patients with Idiopathic Pulmonary Fibrosis**". (Nebraska Medical Center, USA), 2005.9.14.
5. **Invited Lecture in Postgraduate Course of Chinese Respiratory Society. "Pathogenesis and new Treatment in Patients with Idiopathic Pulmonary Fibrosis"**. (Organizer: Yuan-jue Zhu, Peking Union Hospital, Beijing, China), 2005.11.13.
6. **Invited Lecture, Meet the Professor Seminar "New Application of Anti-inflammatory Action of Macrolide"** (American Thoracic Society Annual Meeting 2007 in San Francisco), 2007.5.22.
7. **Invited Lecture "Ethnic difference of acute exacerbation of IPF"** (9th World Association of Sarcoidosis and Other Granulomatous Disorders Meeting 2008 in Athens, Greece), 2008.6.21.
8. **Invited Lecture "EM703 a New Derivative of Erythromycin, Inhibits Lung Fibrosis Induced by TGF-Signaling in Murine and Human Lung Fibroblasts"** EHRlich II 2nd World Conference on Magic Bullets 2008 in Nürnberg, (Germany), 2008.10.3-5.
9. **Invited Lecture "The Treatment of Idiopathic Pulmonary Fibrosis with Pirfenidone" 5th WASOG and Interstitial Lung Disease Meeting** at Charleston, South Carolina, 2009.3.25-27.
10. **Invited Lecture "Ethnic Difference of Acute Deterioration and Treatment Hopes of IPF"** at Keck School of Medicine, University of Southern California (USC), 2010.5.14.
11. **Invited Lecture "Expected Aspects of Macrolide for Amelioration of Severity of A/H1N1 flu 2009"** at the prof. Rubin Research Presentation Meeting in Virginia Commonwealth University (VCU), Dept. of Pediatrics, 2010.11.12.
12. **Invited Lecture "Impact of Clinical Studies on Treatment; Treatment of IPF with pirfenidone in Japan" Advancing in IPF Research (AIR)**, in Rome, Italy. November 30 – December 1, 2012.
13. **Invited Lecture PIPKRA Indonesia Respiratory Society** 14:00 – 14:30; 2014.2.13-14

1. *Plenary symposia 4(PS4)* (attended by 700-1000 Medical doctors): “*Idiopathic Pulmonary Fibrosis: Current Diagnosis and Management of the Difficult Disease*” 14:30 – 14:50
2. *Satellite symposia 13(SS13)*: (attended by around 300 Medical Doctors) “*Idiopathic interstitial pneumonia: diagnosis and treatment approach*”

14. 2015.6.5 Friday; **WASOG 2015**, Satellite Symposium, “*Experience of PFD Treatment with IPF, Jap and Eur*”
Chairing by Carlos AC Pereira, Sao Paulo, Brazil.

15. *Invited Seminar: REG Asia Pacific Summit 2015* in Singapore. ‘*The gap between RCT Management of Real-world clinical setting in rare lung diseases (IPF / ILD)*’ 2015.4.25

16. *Invited Seminar: AFT Meeting* in Singapore. [pirfenidone PMS meeting]
2 lectures at Family Physician and Singapore Thoracic Society Expert Meeting, 2015.3.25

17. **GSK Advisory Board Meeting** (London) ‘*Pirfenidone in a real world setting: Japanese experience in clinical practice*’, 2015.3.22

18. *Invited Seminar of Respiratory Medicine in University of Nevada School of Medicine, “Practical Management of Diffuse Parenchymal Lung Diseases based on the Evidence-based Medicine”* 18 May, 2016.

19. *Invited Lecture “Occupational Interstitial Lung Diseases”, 8th WASOG ILD Congress* at Gdansk, Poland.
Conference Chair; prof. Chair by Anna Dubaniewicz, Gdansk University.; 3 June, 2016.

20. *Invited Lectures* at PIPKRA in Jakarta (**PIPKRA Indonesia University Respiratory Society**), **PG course 1** “*Idiopathic Pulmonary Fibrosis: Diagnostic Approach*”, **PG Course 2** “*Idiopathic Pulmonary Fibrosis: Advanced Therapeutic Approach*”, **Luncheon Symposium: Diffuse Lung Disease** “*Novel Pathogenesis and Treatment of IPF*”; 16-18 Feb, 2017.

21. *Invited Lectures* at 7th International Lung Disease Update 2023. (Pertubuhan Perubatan Pascasiswazah Institut Perubatan Respiratori) Kuala Lumpur, Malaysia. “*Dealing with Adverse Drug Reaction of Anti-Fibrotic Therapy*” 24-26, October, 2023.

22. *Invited Lectures* at KATRD International Conference 2023. (Seoul, South Korea) **Plenary Session 2** “*The Recent Landscape in Development of Anti-fibrotic Agents and Prospects for Future Research*” 8-10 November, 2023.

Certifications/Qualifications

Secretariat, MHLW Priority Disease Study Group on Diffuse Lung Disease

Member of MHLW Priority Study Group on "Development of cellular/molecular pathology-specific treatment of idiopathic interstitial pneumonia"

Member of Study Group of the Ministry of Environment on Effects of Air Pollutants in Humans

Member of Study Group on Intractable Disease of the Bureau of Public Health, Tokyo Metropolitan Government
Councilor of the Japan Society of Sarcoidosis and other Granulomatous Disorders
Manager of the Study Group on Diffuse Lung Disease
Secretary General and Committee Member of the Research Group for Novel Effects of Macrolides
Editor of "Respiratory Molecular Medicine" Journal
Editor of the book "Inflammation, Immunity and Macrolides"
Local Medical Expert on Occupational Accidents, Tokyo Labor Bureau, MHLW
Member of the Committee for Specification of Sufferers from Air Pollution in Adachi Ward, Tokyo
Representative of the Japanese Respiratory Society (from April 2004)
Executive Committee Member of World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG)
(from January 2005)
ATS International Conference Committee Member 2005-2006
Member of the Certification Examination Development Committee of the Japanese Respiratory Society (from
January 2005)
External member of the Committee for Investigation of the Safety of Medical Practice in Toranomon Hospital
(from September 2005)
Associate Professor of Nippon Medical School (from October 2005)
Professor of Graduate School of Medicine, Nippon Medical School (from October 2008)

Editorial Board Member of **Respirology (2008 -)**
International Editorial Board of PNEUMON (GREEK) (from January 2007)
ATS International Lung Health Committee Member (2007 – 2009)
Editorial Board Member of **Pulmonary Medicine (2009 -)**
National Delegate of ERS-Japan (2009 - 2012)
Drug Adverse Reaction Research Committee Member in PMDA (from 2011.6)
Vice President of World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) (from
January 2011)
ATS document development and implementation committee (DDIC) member for IPF guideline (from 2012.5.20)
Visiting Professor of Mie University (from April 2013)
Associate Editor of Respirology Case Reports Journal (from April 2013)
Organize Committee member of WASOG_ Parenchymal Lung Disease (June 2013, Paris)
Part-time Assistant Professor in Kyoto University (from December, 2013)
President Elect of WASOG (October, 2014)
Associate Editor of Respiratory Investigation (from April, 2014)
Research Associate of Graduate School in Mie University (from May, 2016)

The logo for KATRD is a stylized graphic on the left side of the page. It features a large, light blue shape that resembles a flame or a drop, with the letters 'K', 'A', 'T', 'R', and 'D' integrated into it in various colors (yellow, green, blue).

KATRD

The 136th Congress of the Korean Academy of Tuberculosis
and Respiratory Diseases

International Conference 2023

November 8 (Wed) - 10 (Fri), 2023 / Lotte Hotel World, Seoul, Korea

www.katrdic.org

Visiting Professor of Nevada University (from June, 2016)

President of WASOG (October, 2017 to 2020)

Conference Chair of WASOG/Diffuse Lung Diseases 2019 (October, 2019)